BCL2 and B-cell chronic lymphocytic leukemia: A recent clinical trial found that a Bcl-2 mutation, Gly101Val, markedly reduced the affinity of Venetoclax (Bcl-2 specific inhibitor) to Bcl-2, thus conferring acquired resistance by blocking apoptosis in an estimated 25% of CLL patients.